For Research Use Only. Not for Human Consumption.
Recorded market$128.85Recorded exact-size market estimate: 128.85 USD for one 80 mg container (1.610574 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$128.00Member price$96.5025.1% lessMembers save $32.35 on this item vs. recorded market
KPV, GHK-Cu, BPC-157 and TB-500 combination for research.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 80 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$1.21/mg25.1% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 05:03 UTC. 50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500 = 80 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| PSPeptides Oct 11, 2026 UTC | One 80 mg container; 124.99 USD | $1.56/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Ascension Peptides Oct 11, 2026 UTC | One 80 mg container; 120.00 USD | $1.50/mg | lyophilized powder; in stock Price observation; no COA authentication is implied by inclusion. |
| BioEdge Research Labs Oct 11, 2026 UTC | One 80 mg container; 140.00 USD | $1.75/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Anglo Peptides Oct 11, 2026 UTC | One 80 mg container; 80.00 GBP | $1.32/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Pure Lab Peptides Oct 11, 2026 UTC | One 80 mg container; 199.99 USD | $2.50/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Peptidic Research Oct 11, 2026 UTC | One 80 mg container; 170.00 USD | $2.13/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Prime Lab Peptides Oct 11, 2026 UTC | One 80 mg container; 135.00 USD | $1.69/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Healius Peptides Oct 11, 2026 UTC | One 80 mg container; 109.95 AUD | $0.9595/mg | lyophilized powder; BackOrder Price observation; no COA authentication is implied by inclusion. |
| Pure Pharma Australia Oct 11, 2026 UTC | One 80 mg container; 180.00 AUD | $1.57/mg | lyophilized powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Global Bioanalytical Laboratories Oct 11, 2026 UTC | One 80 mg container; 129.35 AUD | $1.13/mg | lyophilized powder; in stock Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “KLOW Blend | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/klow-blend/ Accessed [your access date].
Source page: https://peptideserum.com/product/klow-blend/
A four-peptide combination adding KPV to the GHK-Cu, BPC-157, and TB-500 stack, prepared for inflammation and tissue-biology research.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
KLOW is a blend label rather than a single defined peptide. This guide concerns combinations listing KPV alongside BPC-157, a thymosin-related ingredient and GHK-Cu. The exact composition must be documented for each preparation; the name alone does not establish a standardized formula or clinical effect.
Each ingredient needs its own identity. KPV is the Lys-Pro-Val tripeptide, GHK-Cu is a copper complex, and a thymosin-beta-4 fragment is different from the full-length protein.
A product’s total weight does not reveal the amount of every component. Two blends with the same name or total mass can be materially different research preparations.
The selected directly checked sources concern KPV in experimental inflammation models and GHK-Cu in a small topical study. Neither tested the specified KLOW combination. Their results can explain which ingredient questions are being explored, but cannot establish combined gut, skin or tissue-repair benefits.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Ingredient context: KPV transport and inflammation
Cultured cells and mouse colitis models Reading scope: PubMed abstract |
KPV was studied for transport and inflammatory responses in those experimental systems. | This was not a clinical KLOW trial or evidence of combination benefit. |
| Ingredient context: topical GHK-Cu
Small randomized study after laser resurfacing Reading scope: PubMed abstract |
The trial separated objective comparisons from patient satisfaction. | It did not test KLOW, KPV or an injectable blend. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
The main evidence gap is not simply a small study count. It is the absence, within the checked sources, of a trial of the actual combined intervention. Adding component citations cannot make that missing experiment appear.
A blend can raise questions about interactions and stability that are absent when ingredients are studied separately. A finished mixture therefore needs its own analytical characterization as well as evidence for any clinical claim.
“Anti-inflammatory” describes many different laboratory and clinical outcomes. Suppressing a signaling pathway in cultured cells is not equivalent to controlling a patient’s inflammatory disease.
A credible comparison with GLOW would first define both formulas. Without that, claims that one is stronger, broader or better tolerated are not reproducible.
The reviewed ingredient sources do not establish the combined blend’s safety. A lack of recorded adverse events in a different study cannot be borrowed as the safety profile for KLOW.
There is no KLOW regimen established by the selected component studies. Amounts from different studies cannot simply be added together.
A label’s total mass must be broken down into verified ingredient quantities before even a research concentration can be calculated. That arithmetic still would not determine an effective or safe clinical exposure.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Require a complete composition with each ingredient’s identity and amount. If the thymosin ingredient is described only as TB-500, ask which sequence was actually tested.
A finished-blend report should resolve the individual components and identify the tested batch. Separate raw-material COAs alone cannot establish the final mixture’s composition or stability.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
That would require direct testing of clearly defined formulas. A plausible mechanism or more ingredients does not establish an improved outcome.
No. The species, route, disease model and combined formulation differ. The result should remain attributed to the KPV experiment.
This companion to the KLOW research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
There is no KLOW regimen established by the selected component studies. Amounts from different studies cannot simply be added together.
A label’s total mass must be broken down into verified ingredient quantities before even a research concentration can be calculated. That arithmetic still would not determine an effective or safe clinical exposure.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.